Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma.
Xinan Sheng, Xieqiao Yan, Lin Wang...
https://pubmed.ncbi.nlm.nih.gov/33109737/Actively Recruiting
Led by Zhiquan Hu · Updated on 2026-07-09
170
Participants Needed
22
Research Sites
52 weeks
Total Duration
Researchers are evaluating two different neoadjuvant treatment strategies for adults with muscle-invasive bladder cancer MIBC that expresses the HER2 protein. The study aims to compare disitamab vedotin RC48 combined with gemcitabine versus disitamab vedotin combined with toripalimab before surgery, focusing on the rate of complete tumor removal confirmed by pathology. This is a Phase 3 trial designed to assess if the two treatment approaches are similarly effective in this setting. Participants will be randomly assigned to one of two groups one receives disitamab vedotin plus gemcitabine, and the other receives disitamab vedotin plus toripalimab. Both treatments are given intravenously every two weeks for 3 to 6 cycles, depending on tumor response seen in imaging after the initial 3 cycles. After completing neoadjuvant therapy, all patients undergo radical cystectomy with pelvic lymph node dissection within four weeks. Those eligible will then receive additional adjuvant therapy with disitamab vedotin plus toripalimab for 6 cycles, followed by up to one year of toripalimab maintenance therapy. During the study, participants will have regular imaging scans of the abdomen, pelvis, and chest every 3 to 6 months after surgery, or cystoscopy and imaging if bladder-sparing treatment is chosen. Study staff will contact participants every 3 months to track imaging results and symptoms such as hematuria or respiratory issues, and to document any cancer recurrence or progression. The primary outcome is the pathological complete response rate measured shortly after surgery. Safety is monitored through tracking treatment-related adverse events during neoadjuvant therapy. The total study duration is up to 3 years from start to completion.
CONDITIONS
Neoadjuvant RC48 Plus Gemcitabine in HER2-Expressing MIBC
Z
Zhiquan Hu, M.D.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Zhiquan Hu
Lead Sponsor
Tongji Hospital
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Approximately 6 to 12 weeks
Participants receive disitamab vedotin combined with either gemcitabine or toripalimab every two weeks for 3 to 6 cycles based on tumor response imaging.
Visits every 2 weeks for treatment and imaging assessments
Duration - Up to 4 weeks
Participants undergo radical cystectomy with pelvic lymph node dissection within four weeks after completing neoadjuvant therapy.
1 hospital stay for surgery
Duration - Up to 1 year and 6 months total
Eligible participants receive additional cycles of disitamab vedotin plus toripalimab followed by up to one year of toripalimab maintenance therapy after surgery.
Regular clinic visits for infusions and follow-up
Duration - Up to 3 years
Participants have imaging and cystoscopy as appropriate every 3 to 6 months to monitor for cancer recurrence and side effects. Study staff will contact participants regularly to record symptoms and imaging results.
Visits every 3 months
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Xinan Sheng, Xieqiao Yan, Lin Wang...
https://pubmed.ncbi.nlm.nih.gov/33109737/Haijun Huang, Wei Ma, Xing Zeng...
https://pubmed.ncbi.nlm.nih.gov/41193372/Zhiquan Hu
Lead Sponsor
Tongji Hospital
Collaborating Sponsor